Cargando…

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer

Background. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement particularly in node-positive patients, but optimal dose and schedule remain undetermined. Objectives. This study aimed to assess the feasibility of dose-dense epirubicin and cyclophosphamide fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mirzaei, Hamid Reza, Sabet Rasekh, Parisa, Nasrollahi, Fatemeh, Sabet Rasekh, Parto, Akbari Tirabad, Zahra, Moein, Hamid Reza, Ghaffari Pour, Taban, Hajian, Parastoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800644/ https://www.ncbi.nlm.nih.gov/pubmed/24187626 http://dx.doi.org/10.1155/2013/404396

Ejemplares similares

Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
por: Khoshroo, Sara, et al.
Publicado: (2021)

Evaluating the Prevalence of the Epidermal Growth Factor Receptor in Transitional Cell Carcinoma of Bladder and its Relationship With Other Prognostic Factors
por: Parvin, Mahmoud, et al.
Publicado: (2016)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2014)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)

Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran
por: Khatibi, Mohsen, et al.
Publicado: (2015)

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
por: Bonneterre, J, et al.
Publicado: (2004)

Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in Iran
por: Khatibi, Mohsen, et al.
Publicado: (2014)

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
por: Bartsch, Rupert, et al.
Publicado: (2021)

Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy
por: Li, Hai, et al.
Publicado: (2019)

Supply Chain Challenges in Pharmaceutical Manufacturing Companies: Using Qualitative System Dynamics Methodology
por: Moosivand, Asiye, et al.
Publicado: (2019)

Selecting the Acceptance Criteria of Medicines in the Reimbursement List of Public Health Insurance of Iran, Using the “Borda” Method: a Pilot Study
por: Viyanchi, Amir, et al.
Publicado: (2015)

Administrative Process and Criteria Ranking for Drug Entering Health Insurance List in Iran-TOPSIS-Based Consensus Model
por: Viyanchi, Amir, et al.
Publicado: (2016)

Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial
por: Pizzuti, Laura, et al.
Publicado: (2016)

Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients
por: Chen, Lu, et al.
Publicado: (2018)

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen
por: Bertheau, Philippe, et al.
Publicado: (2007)

Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran
por: Rasekh, Hamid Reza, et al.
Publicado: (2011)

Situation Analysis of R & D Activities: An Empirical Study in Iranian Pharmaceutical Companies
por: Rasekh, Hamid Reza, et al.
Publicado: (2012)

New Product Development in the Pharmaceutical Industry: Evidence from a generic market
por: Yousefi, Nazila, et al.
Publicado: (2017)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
por: Wu, Xian, et al.
Publicado: (2021)

Developing a Model for Agile Supply: an Empirical Study from Iranian Pharmaceutical Supply Chain
por: Rajabzadeh Ghatari, Ali, et al.
Publicado: (2013)

The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
por: Liu, Deyue, et al.
Publicado: (2022)

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
por: Li, Junjie, et al.
Publicado: (2020)

Association between serum Vitamin D levels and prognostic factors in nonmetastatic breast cancer patients
por: Shahrzad, Mohammad Karim, et al.
Publicado: (2022)

Assessment of Correlation between Androgen Receptor CAG Repeat Length and Infertility in Infertile Men Living in Khuzestan, Iran
por: Khatami, Saeid Reza, et al.
Publicado: (2015)

Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market
por: Shabaninejad, Hosein, et al.
Publicado: (2014)

A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer
por: Yao, Xin, et al.
Publicado: (2012)

Costs of Treatment after Renal Transplantation: Is it Worth to Pay More?
por: Salamzadeh, Jamshid, et al.
Publicado: (2014)

The Availability and Affordability of Cardiovascular Medicines for Secondary Prevention in Tehran Province (Iran)
por: Vasheghani Farahani, Ali, et al.
Publicado: (2018)

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
por: Liu, Yin, et al.
Publicado: (2022)

Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors
por: Medioni, Jacques, et al.
Publicado: (2012)

An Analysis of Job Satisfaction among Iranian Pharmacists through Various Job Characteristics
por: Foroughi Moghadam, Mohamad Javad, et al.
Publicado: (2014)

Monetary Value of Quality-Adjusted Life Years (QALY) among Patients with Cardiovascular Disease: a Willingness to Pay Study (WTP)
por: Moradi, Najmeh, et al.
Publicado: (2017)

Safety Assessment of Ocimum Basilicum Hydroalcoholic Extract in Wistar Rats: Acute and Subchronic Toxicity Studies
por: Rasekh, Hamid Reza, et al.
Publicado: (2012)

Drug Literacy in Iran: the Experience of Using “The Single Item Health Literacy Screening (SILS) Tool”
por: Peiravian, Farzad, et al.
Publicado: (2014)

Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors
por: Golestani, Mina, et al.
Publicado: (2014)

Cyclophosphamide and epirubicin-induced diabetes mellitus in breast cancer: A rare occurrence
por: Sharma, Pramod Kumar, et al.
Publicado: (2016)

Distinct effects of epirubicin, cisplatin and cyclophosphamide on ovarian somatic cells of prepuberal ovaries
por: Marcozzi, Serena, et al.
Publicado: (2019)

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer
por: Ishiguro, Hiroshi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_99obi9ji2d5u967ec3oskfsffv